The purpose of the present study was to characterize different ␤-adrenoceptors (␤-ARs) and determine their role in the spontaneously tonic smooth muscle of the internal anal sphincter (IAS). ]iodocyanopindolol to ␤-AR subtypes revealed the presence of a high-affinity site (K d1 ϭ 96.4 Ϯ 8.7 pM; B max1 ϭ 12.5 Ϯ 0.6 fmol/mg protein) and a low-affinity site (K d2 ϭ 1.96 Ϯ 1.7 nM; B max2 ϭ 58.7 Ϯ 4.3 fmol/mg protein). Competition binding with selective ␤-AR antagonists revealed that the high-affinity site correspond to ␤ 1 /␤ 2 -AR and the low affinity site to ␤ 3 -AR. Receptor binding data suggest the predominant presence of ␤ 3 -AR over ␤ 1 /␤ 2 -AR. Western blot studies identified ␤ 1 -, ␤ 2 -, and ␤ 3 -AR subtypes. The presence of ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs was further demonstrated by mRNA analysis using RT-PCR. The studies demonstrate a comprehensive functional and molecular characterization of ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs in IAS smooth muscle. These studies may have important implications in anorectal and other gastrointestinal motility disorders.
I]iodocyanopindolol to ␤-AR subtypes revealed the presence of a high-affinity site (K d1 ϭ 96.4 Ϯ 8.7 pM; B max1 ϭ 12.5 Ϯ 0.6 fmol/mg protein) and a low-affinity site (K d2 ϭ 1.96 Ϯ 1.7 nM; B max2 ϭ 58.7 Ϯ 4.3 fmol/mg protein). Competition binding with selective ␤-AR antagonists revealed that the high-affinity site correspond to ␤ 1 /␤ 2 -AR and the low affinity site to ␤ 3 -AR. Receptor binding data suggest the predominant presence of ␤ 3 -AR over ␤ 1 /␤ 2 -AR. Western blot studies identified ␤ 1 -, ␤ 2 -, and ␤ 3 -AR subtypes. The presence of ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs was further demonstrated by mRNA analysis using RT-PCR. The studies demonstrate a comprehensive functional and molecular characterization of ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs in IAS smooth muscle. These studies may have important implications in anorectal and other gastrointestinal motility disorders.
It is well known that postjunctional ␤-adrenoceptors (␤-ARs) mediate the inhibitory effects of sympathetic nerve stimulation in different smooth muscles including those of the gastrointestinal tract (Manara et al., 1995b; Gauthier et al., 2000) . The intestinal ␤-AR was originally described as a ␤ 1 -and ␤ 2 -AR (Lands et al., 1967) . Further studies with gastrointestinal preparations from several species established the relaxant effect of classical ␤-AR (␤ 1 and ␤ 2 ) agonists (Bennett, 1965; Hedges and Turner, 1969; De Ponti et al., 1996a) . Subsequently, studies investigating ␤-ARs in gastrointestinal smooth muscle from several species demonstrated relaxation responses that were resistant to propranolol and displayed lower affinity to other conventional ␤-AR antagonists (Arch and Kaumann, 1993; Goldberg and Frishman, 1995; Strosberg, 1997; Manara et al., 2000) . This finding, along with the emergence of a new class of ␤-AR agonists described first in adipocytes (Feve et al., 1991) , suggested the presence of an "atypical" class of ␤-ARs. In 1989, Emorine et al. (1989) cloned and sequenced ␤ 3 -AR and found that it shared the pharmacological characteristics of the atypical ␤-AR.
The ␤ 3 -AR has been found in a variety of mammalian tissues (Berkowitz et al., 1995) including white and brown adipocytes (Muzzin et al., 1991) , trachea (Webber and Stock, 1992) , heart (Kaumann and Molenaar, 1996; Gauthier et al., 2000) , gastrointestinal tract (De Ponti et al., 1995; Bardou et al., 1998) , and urinary tract (Tomiyama et al., 1998) . In the GI tract, recent studies have focused on the ability of ␤ 3 -AR specific agonists to cause relaxation in a number of different smooth muscle tissues including rat ileum, jejunum, colon, guinea pig ileum, and duodenum (Manara et al., 1995b) . One of the problems in delineating the pharmacology of ␤-ARs in the gastrointestinal tract has been the lack of subtype-selective agonists and antagonists, especially those for ␤ 3 -AR. Recent in vivo studies have demonstrated the selective, potent, and prolonged relaxant effect of CL 316,243, a selective ␤ 3 -AR agonist, on the sphincteric smooth muscles of the opossum lower esophageal sphincter (DiMarino et al., 2002) , without the significant systemic cardiovascular side effects that are associated with ␤ 1 -and ␤ 2 -AR agonists.
In the past few years, ␤ 3 -agonists have emerged as potential therapeutic agents for several gastrointestinal motility disorders including irritable bowel syndrome (Scarpignato and Pelosini, 1999) . Anorectal dysfunctions such as Hirschsprung's disease, constipation, anal fissures, and hemorrhoids may also be associated with either hypertensive IAS or failure of sphincteric relaxation in response to the rectoanal inhibitory reflex (Azpiroz and Whitehead, 2002) . Characterization of neurohumoral receptors that mediate selective, potent, and prolonged relaxation of IAS and other GI smooth muscles without untoward systemic effects will be of considerable interest in the treatment of anorectal and other GI motility disorders.
The present investigation was carried out to characterize ␤-AR in the gastrointestinal tonic smooth muscle of the IAS by comprehensive studies using a combination of classical pharmacology, receptor binding, and molecular biology approaches.
The aim of the present study is to determine the presence of and characterize the ␤-AR subtypes involved in mediating relaxation of the IAS smooth muscle. We used selective agonists and antagonists to determine the receptor binding profiles of each ␤-AR subtype. The presence of membrane bound ␤-AR and mRNA encoding for the three ␤-AR subtypes was determined through Western blot studies and reverse transcription-polymerase chain reaction (RT-PCR) analysis, respectively.
Materials and Methods
Preparation of Smooth Muscle Strips. Adult male opossums (Didelphis virginiana) weighing 2.5 to 3.5 kg were anesthetized with sodium pentobarbital (50 mg/kg i.p.). Laparotomy was performed, and a part of the rectum along with the anal canal was removed using sharp dissection. The IAS was identified by manometry as high-pressure zone and marked by means of sutures in situ. The animals were sacrificed by exsanguinations; the anorectal region was then dissected out and transferred immediately to oxygenated (95% O 2 ϩ 5% CO 2 ) Krebs' physiological solution of the following composition: 118.07 mM NaCl, 4.69 mM KCl, 2.52 mM CaCl 2 , 1.16 mM MgSO 4 , 1.01 mM NaH 2 PO 4 , 25 mM NaHCO 3 , and 11.10 mM glucose. A longitudinal incision along the length of isolated anorectal region was made, and the tissue was pinned flat in a Sylgard (Dow Corning Corp., Midland, MI)-coated Petri dish. Once the lumen was fully exposed, the mucosa and submucosa were removed carefully by sharp dissection. The tissue was then turned on the serosal side, and all extraneous tissue including the outer longitudinal muscle was removed. Circular smooth muscle strips of the IAS (approximately 1 ϫ 10 mm) were prepared and tied on either end using 3-0 silk suture in preparation for measurement of isometric tension.
The experimental protocol of the study was approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University in accordance with the recommendations of the American Association for the Accreditation of Laboratory Animal Care.
Measurement of Isometric Tension. The smooth muscle strips were transferred to 2-ml muscle baths (Radnoti Glass Technology, Inc., Monrovia, CA) containing oxygenated Krebs' solution at 35°C. One end of the muscle strip was anchored at the bottom of the muscle bath while the other end was connected to a force transducer (model FT03; Grass Instruments, Quincy, MA). Isometric tension was recorded by the PowerLab/8SP data acquisition system using Chart 4.1.2 (ADInstruments, Grand Junction, CO). Each smooth muscle strip was initially stretched to a tension of 0.7 g. The muscle strips were then given at least an hour to equilibrate, during which time they were washed with Krebs' solution every 15 min. Only smooth muscle strips that developed spontaneous tone and responded to electrical field stimulation were used in this study. The changes in tension from various drugs were expressed as the percent maximal relaxation achieved by 50 mM EGTA, at the end of each experiment. Each smooth muscle served as its own control.
Drug Responses. To determine the concentration-response curves (CRCs) with ␤ 1 -, ␤ 2 -, and ␤ 3 -AR agonists on the basal tone of the IAS smooth muscles, xamoterol, procaterol, and ZD 7114 [(S)-4-[2-hydroxy-3-phenoxypropylaminoethoxy]-N-(2-methoxyethyl)phenoxyacetamide], respectively, were added to the muscle bath in cumulative concentrations (Rattan and Moummi, 1989) . Successive concentrations of the agonists were not added until the response of the previous concentration stabilized. When no effect was observed, 10 minutes were allowed between additions of different concentrations. In preliminary studies, when a single concentration was used, we noted that this was an appropriate time to gauge the maximal effect of a given concentration of the agonist. No difference in the results occurred with longer exposures. To determine the effects of ␤ 1 -, ␤ 2 -, and Ϫ8 to 1 ϫ 10 Ϫ6 M), were added 30 min before obtaining the CRC of the test agonist.
␤-Adrenoceptor (␤-AR) Analysis by Western Blot. Western blot analysis of ␤ 1 -, ␤ 2 -, and ␤ 3 -AR in the IAS and rectum of the opossum was performed according to the protocol of Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Circular smooth muscles tissues of the IAS and rectum were cut into small pieces (2 ϫ 2 mm cubes) and rapidly homogenized in 3 ml of boiling lysis buffer (1% SDS, 1.0 mM sodium orthovanadate, 10 mM Tris, pH 7.4) and then put into the microwave for 10 s. The homogenates were centrifuged (16,000g, 4°C) for 15 min. The pellet obtained was dissolved in Krebs' buffer (composition already described) containing 1 mM EDTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride (combined pH of 7.6). The protein contents were determined by the method described by Lowry et al. (1951) using bovine serum albumin as the standard.
All of the samples were mixed with 2ϫ sample buffer (125 mM Tris, pH 6.8, 4% SDS, 10% glycerol, 0.006% bromphenol blue, 2% ␤-mercaptoethanol) and boiled for 4 min. A total of 20 l (40 g total protein) of each sample was applied to commercially available 7.5% SDS polyacrylamide gel PAGEr Gold Gel (Cambrex Bio Science Walkersville, Inc., Walkersville, MD) applied to a 7.5% SDS-polyacrylamide gel apparatus by the method of Laemmli (1970) , using 150 V for 1 h. The separated proteins were electrophoretically transferred to a nitrocellulose membrane (NCM) at 4°C for 90 min at 100 V. To block nonspecific antibody binding, the NCMs were immersed overnight at 4°C in Super Block Tris-buffered saline/Tween blocking buffer (Pierce Biotechnology, Rockford, IL). The NCM was divided into three smaller sections labeled as ␤ 1 , ␤ 2 , and ␤ 3 . The NCMs were then incubated with the respective diluted isoform specific primary (1°) antibodies corresponding to the specific ␤-AR subtype. The NCMs were incubated with rabbit ␤ 1 , ␤ 2 , and goat ␤ 3 polyclonal antibodies, respectively (Santa Cruz Biotechnology Inc.) at a dilution of 1:500. All membranes were incubated with 1°antibody for 1 h at room temperature. The membranes were then washed with Trisbuffered saline/Tween three times. Afterward, the membranes corresponding to ␤ 1 and ␤ 2 were incubated separately in 1:1000 diluted horseradish peroxidase-conjugated donkey anti-rabbit IgG (Amersham Biosciences Inc., Piscataway, NJ) in 2°antibody buffer for 1 h at room temperature. The remaining membrane was incubated in 1:5000 diluted horseradish peroxidase-conjugated bovine anti-goat IgG (Santa Cruz Biotechnology Inc.) in 2°antibody buffer. The bands were identified by chemiluminescence using the ECL detection system and Hyperfilm MP (Amersham Biosciences). Densitometric analysis of the bands was performed using Image Pro Plus 4.0 software (Media Cybernetics, Silver Spring, MD).
Membrane Preparation for Receptor Binding Studies. The circular smooth muscle of the IAS was dissected free by the aforementioned procedure and placed immediately in ice-cold Krebs' buffer (composition already described above) containing 1 mM EDTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride (combined pH of 7.6). The IAS was minced with scissors and homogenized in 5 volumes of ice-cold TED buffer (20 mM Tris Cl, 1 mM EDTA, 1 mM dithioreitol, pH 8) by the use of a Tekmar Tissuemizer (Tekmar-Dohrmann, Mason, OH) for 15 s. The homogenates were centrifuged at 100,000g for 1 h at 4°C. The supernatant was filtered through a 500-m Nitex mesh. The pellets were resuspended in cold Krebs' buffer (pH 7.6) and stored at Ϫ80°C until used. Protein content was determined by the method of Lowry et al. (1951) .
Radioligand Binding Studies. 0, 15, 30, 45, 60, 90, 120, 150 , and 180 min. The experiments were carried out in the presence or absence of 100 M propranolol (a nonselective ␤-AR antagonist). The incubation mixture was composed of 50 mM Tris HCl buffer, pH 7.4, containing 10 mM MgCl 2 and 1 mM EDTA in a final volume of 250 l. A time course (using the above-mentioned time points) was carried out in duplicate at 35°C to determine the optimal time needed for equilibrium. The incubation was terminated by rapid filtration through Whatman GF/C glass-fiber filters (24-mm circles) (Whatman, Clifton, NJ) using a 1225 sampling manifold (Millipore Corp., Bedford, MA), followed by washing three times with 5 ml of ice-cold 25 mM Tris HCl buffer, pH 7.4. The filters were counted in the AutoGamma Counting System (model 5550; PerkinElmer Life Sciences, Boston, MA) at an efficiency of 80%. Specific binding was calculated by subtracting nonspecific binding from total binding.
For saturation assays, membranes were incubated at 37°C for 120 min with increasing concentrations of [ 125 I]CYP (5-3000 pM). All values in binding experiments are the average of duplicates. Specific binding was defined as binding inhibited by 100 M propranolol. The equilibrium dissociation constant (K d ) and the maximum binding capacity (B max ) were determined by nonlinear regression analysis by GraphPad Prism software (GraphPad Software Inc., San Diego, CA). K d is the concentration of ligand required to occupy 50% of the binding sites. B max is defined as the maximal specific binding obtained with increase in concentration of radioligand, and it is a measure of receptor density in the tissue under investigation. Displacement experiments were performed with varying amounts of [ 125 I]CYP, depending on the appropriate K d of the high-and lowaffinity sites of the IAS. In the IAS, 66 pM and 1.61 nM [
125 I]CYP were used in the high-and low-affinity sites, respectively. The K i value was calculated by the Cheng-Prusoff equation (Cheng and Prusoff, 1973) as:
, where IC 50 represents the concentration of competitor causing 50% inhibition and L signifies the concentration of radioligand.
Isolation and Quantification of Total RNA. Tissue specimens from the circular smooth muscle of the IAS were carefully dissected and homogenized as described under Membrane Preparation for Receptor Binding Studies. Total RNA was extracted from the tissue homogenate using the TRI reagent (Molecular Research Center, Cincinnati, OH) protocol based on the method of Chomczynski and Sacchi (1987) . RNA samples were then dissolved in diethylpyrocarbonate (DEPC)-treated water (pH 7.5). The optical density (OD) of each sample was determined by a UV-visible spectrophotometer (Amersham Biosciences) at a wavelength of 260 nm ( 260 ). The yield and quality of the RNA were assessed by measuring the OD 260 /OD 280 ratio. Preparation and Amplification of cDNA Encoding ␤ 1 -, ␤ 2 -, and ␤ 3 -ARs (RT-PCR Analysis). RNA samples of 2 l (1 g) that were of acceptable quality were used as templates for the synthesis of cDNA. Primers for ␤ 1 -, ␤ 2 -, and ␤ 3 -AR, and ␤-actin (internal standard), based on the previous report (Dincer, 2002) , were synthesized by Thomas Jefferson University facilities (Kimmel Cancer Institute, Nucleic Acid Facility). The sequence and accession numbers listed in Table 1 are based on published sequences in the National Center for Biotechnology Information GenBank database (http:// www3.ncbi.nlm.nih.gov/entrez). cDNAs were synthesized by reverse transcription of 1.0 g of each total RNA. The reaction mixture consisted of 10ϫ reverse transcription buffer, deoxynucleoside-5Ј-triphosphates (20 mM), MgCl 2 (25 mM), 18 U of RNasin ribonuclease inhibitor, and 20 U of AMV reverse transcriptase in a total volume of 20 l. The contents of reaction mixture were purchased from Promega (Madison, WI). After a brief centrifugation, the reaction mixtures were incubated at 42°C for 45 min and then at 95°C for 5 min.
PCR amplification was done on segments of cDNA encoding each of the three subtypes of ␤-AR using gene-specific primers as a way of determining the amount of transcripts present. The PCR reaction mixture was added directly to RT tubes and consisted of 10ϫ reaction buffer, 25 mM MgCl 2 , 3.5 l of recombinant TaqDNA polymerase (Takara Shuzo Co., Shiga, Japan), and 20 mM concentrations of the respective sense and antisense primers. DEPC water was added for a final volume of 50 l. PCR amplification was carried out in a Mark cycle gradient thermal sequencer (Eppendorf, Inc., Westbury, NY). After initial heating of samples at 95°C, each cycle of amplification consisted of 45 s at 94°C, followed by 45 s at 60°C, and 2 min of extension at 72°C; this sequence was repeated for a total of 38 All agents except SR 59230A and ZD 7114 were dissolved and diluted in Krebs' buffer. Initial stock solutions (10 Ϫ2 M) of SR 59230A and ZD 7114 were prepared using DMSO and were then diluted accordingly with Krebs' buffer to arrive at the desired final concentrations in the muscle baths. The amounts and concentrations of DMSO used for any of the final concentrations had no effect on the basal tone of the IAS smooth muscle.
Data Analysis. The fall in basal tension of the IAS smooth muscle following administration of agonists was expressed as the percentage of maximal relaxation as explained above. The results were expressed as means Ϯ S.E. of different experiments. The statistical significance between different groups was determined by analysis of variance and by paired or unpaired t test. A p value smaller than 0.05 was considered significant. Agonist potencies, pA 2 of antagonists, and receptor binding data (B max , K d , and K i ) were calculated using GraphPad Prism software. pA 2 values were calculated based on the earlier method (Arunlakshana and Schild, 1959) .
Results

Effect of ZD 7114 on the Basal Tone of IAS Smooth
Muscle. The ␤ 3 -AR agonist ZD 7114 (formerly ICI D7114) (Growcott et al., 1993b ) produced a concentration-dependent fall in the basal tension of the IAS smooth muscle (Fig. 1A) with an EC 50 value of 5.30 ϫ 10 Ϫ8 M (n ϭ 8 -10). The concentration causing maximal relaxation (EC max ) was 1 ϫ 10 Ϫ6 M. The maximal relaxation in different experiments ranged from 80.7 to 88.5%. The selective ␤ 3 -AR antagonist SR 59230A (De Ponti et al., 1996b) significantly attenuated the relaxant response to ZD 7114 in a concentration-dependent manner (p Ͻ 0.05; n ϭ 5-8; Fig. 1A) . A Schild plot produced a line with a slope of 0.90 Ϯ 0.15 (Fig. 1B) and a corresponding pA 2 value of 7.8 Ϯ 0.24.
Both the selective ␤ 1 -AR antagonist CGP 20712A (Dooley et al., 1986) (1 ϫ 10 Ϫ7 M) and the selective ␤ 2 -AR antagonist ICI 118551 (Bilski et al., 1983) (1 ϫ 10 Ϫ7 M) failed to produce any significant shifts in the CRCs of ZD 7114 (p Ͼ 0.05; n ϭ 5-8; Fig. 1C ). The EC 50 and pA 2 values of ␤ 3 -and other ␤-AR agonists and antagonists are given in Table 2 .
Effect of Procaterol on the Basal Tone of IAS Smooth Muscle. Procaterol, a ␤ 2 -AR selective agonist (Kotsonis and Majewski, 1994 ) produced a concentration-dependent fall in basal tension of the IAS smooth muscle with an EC 50 value of 2.51 ϫ 10 Ϫ8 M (n ϭ 5-8) (Fig. 2A) . The concentration causing maximal relaxation (EC max ) was 3 ϫ 10 Ϫ6 M. The maximal relaxation in different experiments ranged from 79.1 to 83.7%. The selective ␤ 2 -AR antagonist ICI 118551 (Bilski et The selective ␤ 1 -AR antagonist CGP 20712A (1 ϫ 10 Ϫ7 M) and the selective ␤ 3 -AR antagonist SR 59230A (1 ϫ 10 Ϫ7 M) did not produce any significant shifts in the CRC of procaterol (p Ͻ 0.05; n ϭ 5-8; Fig. 2C ).
Effect of Xamoterol on the Basal Tone of IAS Smooth Muscle.
The ␤ 1 -AR agonist xamoterol (Malta et al., 1985) produced a concentration-dependent fall in the basal tension of the IAS smooth muscle (Fig. 3A) with an EC 50 value of 1.02 ϫ 10 Ϫ7 M (n ϭ 5-8). The concentration causing maximal relaxation (EC max ) was 3 ϫ 10 Ϫ6 M. The maximal relaxation in different experiments ranged from 71.5 to 78.7%. The selective ␤ 1 -AR antagonist CGP 20712A (Dooley et al., 1986) caused a significant shift in the CRC of xamoterol in a concentration-dependent manner (p Ͻ 0.05; n ϭ 5-8; Fig. 3A) . A Schild plot produced a line with a slope of 0.82 Ϯ 0.08 (Fig.  3B ) and a corresponding pA 2 value of 7.12 Ϯ 0.18.
The selective ␤ 2 -AR antagonist ICI 118551 (1 ϫ 10 Ϫ7 M) did not inhibit relaxation by xamoterol at concentrations below 3 ϫ 10 Ϫ7 M. However, ICI 118551 significantly reduced the xamoterol-mediated relaxation at higher concentrations (p Ͻ 0.05; n ϭ 5-8). The selective ␤ 3 -AR antagonist SR 59230A (1 ϫ 10 Ϫ7 M) did not produce any significant shifts in the CRC of xamoterol (p Ͻ 0.05; n ϭ 4; Fig. 3B ).
Receptor Binding Studies on ␤-ARs in IAS Smooth Muscle. To characterize and determine the levels of ␤-ARs in the IAS, we conducted radioligand binding studies with [ 125 I]CYP. Based on reports that [ 125 I]CYP has a significantly lower affinity for ␤ 1 /␤ 2 -AR than for ␤ 3 -AR (Dunigan et al., 2000; Kohout et al., 2001) , we investigated the binding profiles of the three ␤-AR subtypes in the IAS. Initially, to determine the appropriate time need for the equilibrium, a time course was plotted. [
125 I]CYP specifically bound to membrane preparations of the IAS in a time-dependent fashion, with equilibrium achieved at 90 min (35°C), and remained constant for 180 min (data not shown).
When membrane preparations derived from the circular smooth muscle layer of the IAS were incubated with increasing concentrations of radioligand (5-3000 pM) and 100 M propranolol, the nonselective ␤-antagonist, the specific binding of [ 125 I]CYP was found to be saturable with a plateau of saturation between 750 and 1200 pM radioligand (Fig. 4A) . Sigmoid representation of the data illustrates the binding of [ 125 I]CYP over large concentration ranges from the high affinity site (picomolar) to the low affinity site (nanomolar) (Fig. 4B) . The two populations of ␤-ARs were also evident by the curvilinear Scatchard plot of the data (Fig. 4C) . Nonlinear regression analysis revealed that the saturation binding (Fig. 6) . Similar trends were seen with the respective selective ␤ 1 -, ␤ 2 -, and ␤ 3 -AR agonists (data not shown). The K i value was calculated according to the Cheng-Prusoff equation (Cheng and Prusoff, 1973) , and the resultant values at both the high-and low-affinity sites are listed in Table 3 .
Additional calculations based on specific binding revealed the predominant presence of low-affinity ␤ 3 -ARs. From the entire population of ␤-ARs, high-affinity (␤ 1 /␤ 2 -AR) constituted 21.3% and low affinity (␤ 3 -ARs) comprised 78.7%. 
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Determination of ␤ 1 -, ␤ 2 -, and ␤ 3 -AR Membrane Protein in the IAS and Rectum. To identify and quantify ␤-AR protein expression in the rectum and IAS, the membrane preparations were fractionated by SDS-polyacrylamide gel electrophoresis and subjected to Western blotting by primary antibodies specific to each ␤-AR subtype (see Materials and Ϫ8 M) causes a significant and concentration-dependent inhibition of the IAS smooth muscle relaxation by xamoterol (ૺ, p Ͻ 0.05; n ϭ 5-8). B, Schild plot of different concentrations of CGP 20712A versus log(r Ϫ 1) of xamoterol. The pA 2 value for SR 59230A in antagonizing xamoterol-induced relaxation of the IAS smooth muscle is 7.12. C, influence of ␤ 2 -and ␤ 3 -AR antagonists ICI 118,551 and SR 59230A, respectively, on percent maximal fall in basal IAS tone by xamoterol. Data show that the ␤ 1 -AR agonist-mediated fall in the basal tone of the IAS smooth muscle was not significantly modified by SR 59230A (p Ͼ 0.05; n ϭ 5-8) but was modestly antagonized by ICI 118551 (ૺ, p Ͻ 0.05; n ϭ 5-8).
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Methods). All three subtypes of ␤-AR were found to be present in the rectum and IAS membranes as shown by the representative blots in Fig. 7 . The blots demonstrate the relative distribution of membrane receptor proteins for ␤ 1 -AR, (63 kDa), ␤ 2 -AR (68 kDa), and ␤ 3 -AR (65 kDa) in these tissues. Data suggest that the distribution of the three subtypes of membrane ␤-AR in these tissues was similar (p Ͼ 0.05; Fig. 7) .
Detection of ␤-AR mRNA in the IAS Using RT-PCR.
RT-PCR amplification was used to detect ␤ 1 -, ␤ 2 -, and ␤ 3 -AR, and ␤-actin mRNA in the circular smooth muscle layer of the IAS. To ensure that the PCR products were exclusively derived from mRNA, total RNA samples were treated with DNase to eliminate genomic DNA. As shown in Fig. 8 , the resultant PCR products demonstrated the expected sizes of 608 (␤ 1 -AR), 194 (␤ 2 -AR), and 444 bp (␤ 3 -AR). The PCR product for ␤-actin, an internal standard, was also detected in each preparation at its expected size of 387 bp.
Discussion
The studies demonstrate a systematic and comprehensive characterization of ␤-adrenoceptors (␤-ARs) in the tonic smooth muscle of the gastrointestinal tract. The IAS smooth muscle served as the prototype using functional, classical pharmacology, molecular, and receptor binding approaches. The studies demonstrate: 1) the presence of membranebound ␤-AR through Western blotting and ␤-AR mRNA through RT-PCR; 2) the role of a heterogeneous population of ␤-ARs (␤ 1 , ␤ 2 , and ␤ 3 ) in mediating potent relaxation of the Table 3 . The contribution of the three ␤-AR subtypes in mediating IAS smooth muscle relaxation is in general agreement with previous reports in different smooth muscles including the GI tract (Goldberg and Frishman, 1995; De Ponti et al., 1996a; Roberts et al., 1997; Strosberg, 1997) . The conclusions are based on the ability of ␤ 1 -, ␤ 2 -, and ␤ 3 -agonists to cause a full relaxation that is selectively antagonized by their respective antagonists. ZD 7114, a ␤ 3 -selective agonist (Growcott et al., 1993b) , produces a concentration-dependent relaxation of the IAS smooth muscle that is antagonized by the ␤ 3 antagonist SR 59230A (De Ponti et al., 1996b) but not by CGP 20712A or ICI 118551 (␤ 1 -and ␤ 2 -AR antagonists, respectively). The affinity values for antagonism by SR 59230A (pA 2 of 7.8) are consistent with previous studies in guinea pig ileum (pA 2 , 7.7) (Roberts et al., 1999) and human colon (pA 2 , 8.3) (De Ponti et al., 1996b) . Procaterol, a ␤ 2 -selective agonist (Kotsonis and Majewski, 1994) , also causes a concentration-dependent relaxation of the smooth muscle strips with a pEC 50 of 7.6, whereas ICI 118,551 (␤ 2 -selective antagonist) (Bilski et al., 1983) antagonizes this relaxation with a pA 2 value of 7.7. This is consistent with pA 2 values reported by Strosberg (1997) . Likewise, xamoterol (␤ 1 agonist) (Malta et al., 1985) , causes a concentration-dependent relaxation of the IAS smooth muscle that is selectively antagonized by CGP 20712A (␤ 1 -AR antagonist).
In the rat (Roberts et al., 1999; Brown and Summers, 2001 ) and mouse (Hutchinson et al., 2001 ) ileum, it has been shown that ␤ 3 -ARs play a predominant role, whereas ␤ 1 -ARs have only a small role in smooth muscle relaxation. The presence of atypical or ␤ 3 -ARs was established in rat ileum by [ 125 I]CYP binding studies (Roberts et al., 1995) and by ␤ 3 -mRNA on RT-PCR analysis (Roberts et al., 1999) . Roberts et al. (1995 Roberts et al. ( , 1999 were able to show the presence of ␤ 3 -AR but not those of ␤ 1 -and ␤ 2 -AR binding sites, even under classical binding conditions. Roberts et al. (1995 Roberts et al. ( , 1999 did, however, find an abundance of ␤ 2 -AR mRNA, in addition to ␤ 3 . Nevertheless, the role of ␤ 2 -AR was discounted because smooth muscle relaxation caused by zinterol (␤ 2 -AR-selective agonist) was antagonized by the ␤ 3 antagonist SR 58894A and not by ICI 118551. The exact reason for the differences in the functional, binding, and molecular findings in these studies has not been fully delineated.
In contrast, the results of our studies in the IAS are in agreement with those in human colonic smooth muscle (De Ponti et al., 1996b) showing that the respective ␤ 1 -and ␤ 2 -selective antagonists CGP 20712A and ICI 118551 inhibit isoprenaline-mediated relaxation, which is further inhibited by SR 59230A. Differences between various studies may be reconciled on the basis of variations in species and tissues. The present studies, like those in human colon (De Ponti et al., 1996b) , were conducted in spontaneously tonic smooth muscle, compared with others in which contraction was elicited by different contractile agonists. Whether such contractile agonists have attenuating effects in the functional expression of different ␤-ARs remains to be determined.
Receptor binding, Western blot, and RT-PCR studies provide additional support in favor of the functional data. The receptor binding studies demonstrate, for the first time in the GI tract, the presence of two binding sites. These binding sites correspond to high affinity (R H ) ␤ 1 /␤ 2 and low affinity (R L ) ␤ 3 sites. We identified these binding sites with K d values of 96 pM and 1.96 nM, respectively. The K d values of the respective binding sites are similar to those described in adipocytes and Chinese hamster ovary (CHO) cells (Feve et al., 1991) . Two classes of binding sites were identified using competition studies with ␤-AR subtype-selective antagonists. The rank order potency of the antagonists at the high-affinity site is ICI 118551 Ͼ CGP 20712A Ͼ SR 59230A with K i values of 3.04 ϫ 10 Ϫ8 , 1.14 ϫ 10 Ϫ7 , and 8.53 ϫ 10 Ϫ7 M, respectively. When radioligand concentrations were employed in the lowaffinity range (1.61 nM), the potency was reversed, with SR 59230 Ͼ ICI 118551 Ͼ CGP 20712A. The corresponding K i values with these antagonists were 4.81 ϫ 10 Ϫ8 , 6.80 ϫ 10 Ϫ7 , and 1.78 ϫ 10 Ϫ6 M, respectively. The K i values of CGP 201712A and ICI 118551 at the R H are consistent with those reported at ␤ 1 -and ␤ 2 -ARs in CHO cells (Mejean et al., 1995) . The K i value for SR 59230A at the R L is similar to that of the ␤ 3 -AR found in rat colon (Manara et al., 1995a) . The K i values of CGP 20712A and ICI 118551 are similar to those reported in guinea pig ileum and vascular smooth muscles (Kohout et al., 2001) . ZD 7114 was first described as a selective ␤ 3 -AR agonist in brown fat and guinea pig ileum (Holloway et al., 1991) . Some subsequent studies have described ZD 7114 as having atypical ␤ 3 -AR antagonistic effects in certain tissues (Growcott et al., 1993a) . In the IAS smooth muscle, ZD 7114 behaves as a full ␤ 3 -AR-selective agonist causing relaxation that is potently inhibited by SR 59230A. Therefore, the actions of ZD 7114 may be tissue-and species-specific. SR 59230A was developed as the first ␤ 3 -AR-selective antagonist for the gut (Manara et al., 1995a) . Recently, Horinouchi and Koike (2001) have raised the possibility that the effects of SR 59230A are tissue-specific. In the guinea pig gastric fundus and duodenum, SR 59230A may possess atypical ␤-AR-agonistic activity by recognizing an aminotetralin moiety in the ␤-AR. In our study, however, SR 59230A was found to be a selective ␤ 3 -AR antagonist with a pA 2 value of 7.8. It causes a concentration-dependent rightward shift in the CRC of ZD 7114 without modifying the effects of ␤ 1 -and ␤ 2 -AR agonists. In addition, SR 59230A alone does not cause a fall in IAS basal tone at concentrations up to 1 ϫ 10 Ϫ4 M. It is possible that the presence of a bulky group on the arylethanolamine or aryloxypropanololamine side chain on both ZD 7114 and SR 59230A (Horinouchi and Koike, 2001) may render the receptor tissue-and species-specific. However, the opposing actions of ZD 7114 and SR 59230A in the IAS may not support that concept.
Receptor binding analysis reveals a higher receptor density of ␤ 3 -AR in the IAS smooth muscle. This is supported by the severalfold higher B max in the case of low-affinity ␤-AR (␤ 3 -AR) compared with high-affinity ␤-〈R (␤ 1 /␤ 2 -AR). With this information, one would have expected higher potencies of ␤ 3 -versus ␤ 1 -and ␤ 2 -AR agonists in causing IAS smooth muscle relaxation. The functional studies, however, show that in this respect, ␤ 1 -, ␤ 2 -, and ␤ 3 -agonists are nearly equipotent. We speculate three possible explanations for this disparity. The first and simplest explanation is the lack of effective ␤ 3 -AR agonists as compared with ␤ 1 -and ␤ 2 -AR agonists for the IAS smooth muscle at the present time. Second, ␤ 3 -AR in the IAS smooth muscle may have a large number of spare receptors. Third, ␤ 3 -AR may represent a heterogeneous population such as ␤ 3a -and ␤ 3b -ARs, as suggested by the recent studies in CHO (Hutchinson et al., 2002) . Furthermore, the activation and signal transduction of such a ␤ 3a -and ␤ 3b -AR complex may prevent the full potency of the ␤ 3 -AR agonist. Therefore, it is no surprise that the ␤ 3 -AR agonist ZD 7114 has variable effects in different GI smooth muscle preparations (Growcott et al., 1993a,b) . The involvement of ␤ 3a -and ␤ 3b -AR complex and the exact signal transduction involved in ␤ 3 -AR-mediated IAS relaxation by agonists such as ZD 7114 remains to be determined.
In addition to receptor binding studies, the presence of ␤-AR in the IAS smooth muscle is further demonstrated by Western blot and RT-PCR studies. Western blot studies using primary antibodies specific to each ␤-AR subtype reveal the presence of all three subtypes of ␤-AR (␤ 1 -AR, 63 kDa; ␤ 2 -AR, 68 kDa; and ␤ 3 -AR, 65 kDa) in the rectum and IAS membranes. RT-PCR amplification was used to detect ␤ 1 -, ␤ 2 -, and ␤ 3 -AR in the circular smooth muscle layer of the IAS. The PCR products demonstrated the expected sizes of 608 (␤ 1 -AR), 194 (␤ 2 -AR), and 444 bp (␤ 3 -AR).
The present studies, therefore, provide comprehensive evidence for the presence and actions of ␤ 1 -, ␤ 2 -, and ␤ 3 -AR in IAS smooth muscle. In light of these findings, combined with the previously described actions of ␤ 3 -AR activation in the lower esophageal sphincter (DiMarino et al., 2002) with limited side effects and prolonged smooth muscle relaxation, we suggest that ␤ 3 -AR agonists in particular may have considerable physiological and therapeutic implications in anorectal and other spastic gastrointestinal motility disorders.
